Project Grant R01CA305818
Award Date 6/15/26
Completion Date 5/31/31
Dollars Obligated $664K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
- Federal Grant Award Summary Northwestern University received a $544,080 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) on June 1, 2026, for the Physical and Functional Improvement via Cancer Rehabilitation Triaging (PIVOT) Trial. The project, extending through May 31, 2031, will develop and evaluate the 4RS Cancer Rehabilitation Triaging System—an electronic health record (EHR)-integrated platform designed to...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $2,970,010 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 16, 2025, with completion targeted for August 31, 2029. The research initiative focuses on elucidating the tumorigenic mechanisms of somatic truncation mutations in KMT2D, which encodes the histone methyltransferase MLL4 (mixed-lineage leukemia 4), particularly as...
- Federal Project Grant Award Summary The National Cancer Institute awarded The MGH Institute of Health Professions, Inc. a $696,498 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) effective May 1, 2026, through April 30, 2031, to develop and optimize a multicomponent intervention designed to improve functional recovery and quality of life among breast cancer survivors. The research employs the Multiphase Optimization Strategy (MOST) framework to systematically evaluate three...
- Federal Project Grant Award Summary Northwestern University received a $496,357 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on April 17, 2026, with a completion date of March 31, 2031. The award supports research aimed at disrupting immunosuppression mechanisms in glioblastoma multiforme (GBM), the most aggressive primary brain tumor. The project investigates the peri-necrotic microenvironment where tumor-associated...
- Federal Grant Award Summary Award Details: Funding Agency: National Cancer Institute Federal Grant Program: Cancer Cause and Prevention Research (CFDA 93.393) Awardee: Northwestern University, Sponsored Research Division Total Obligated Funding: $645,460 Award Period: August 1, 2025 – July 31, 2030 Northwestern University will conduct a five-year research project to elucidate the mechanisms underlying nilotinib-induced artery disease (NIAD) and develop predictive tools to identify patients at...
- Federal Grant Award Summary Northwestern University received a $2.1 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded September 23, 2025, with completion targeted for August 31, 2029. The project aims to determine genotypic, phenotypic, and evolutionary trajectories of treatment resistance to radiotherapy by analyzing matched pre- and post-radiotherapy genomes from patient tissue and patient-derived xenografts (PDXs)...
- Federal Project Grant Award Summary Northwestern University received a $954,436 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective September 23, 2025, with a completion date of July 31, 2030. The research project investigates the persistence of leukemia stem cells (LSCs) in chronic myeloid leukemia (CML) patients during tyrosine kinase inhibitor (TKI) treatment, with particular focus on LSC interactions with CD8+ T...
- Summary of Federal Project Grant Award The National Cancer Institute (NCI) awarded Northwestern University a $631,487 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period of June 1, 2026 through May 31, 2031. The award supports research to define the determinants of lineage identity programming in LKB1-mutant lung cancer and identify therapeutic resistance mechanisms. The research will elucidate how LKB1 (Serine/Threonine Kinase 11) loss regulates...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of Miami a $2.75M Project Grant on September 12, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a four-year clinical research study examining the effects of remotely-delivered cognitive behavioral stress management (R-CBSM) on cancer-accelerated aging in distressed breast cancer survivors aged 50 and older. The study will enroll 192 breast cancer survivors who completed...
- Federal Grant Award Summary The National Cancer Institute awarded a $731,503 Project Grant to Sloan-Kettering Institute for Cancer Research, effective June 1, 2026 through May 31, 2031, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds a randomized controlled trial (RCT) evaluating Brief Behavioral Activation for Older Adult Cancer Survivors (BBA-OACS), a telehealth-based psychotherapy intervention designed to address clinically significant depression among...